{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1070299086502397312.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@language":"en","@value":"Sarkar, Bidhan Chandra"},{"@language":"ja","@value":"サルカル, ビードン チャンドラ"},{"@language":"ja-Kana","@value":"サルカル, ビードン チャンドラ"}],"foaf:familyName":[{"@language":"en","@value":"Sarkar"},{"@language":"ja","@value":"サルカル"},{"@language":"ja-Kana","@value":"サルカル"}],"foaf:givenName":[{"@language":"en","@value":"Bidhan Chandra"},{"@language":"ja","@value":"ビードン チャンドラ"},{"@language":"ja-Kana","@value":"ビードン チャンドラ"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1050580328307515648","@type":"Article","resourceType":"学術雑誌論文(journal article)","productIdentifier":[{"@type":"HDL","@value":"http://hdl.handle.net/10458/0002000435"},{"@type":"URI","@value":"https://miyazaki-u.repo.nii.ac.jp/records/2000435"},{"@type":"DOI","@value":"10.1038/s41598-018-32205-8"},{"@type":"URI","@value":"https://www.nature.com/articles/s41598-018-32205-8.pdf"},{"@type":"URI","@value":"https://www.nature.com/articles/s41598-018-32205-8"},{"@type":"PMID","@value":"30214063"}],"notation":[{"@language":"en","@value":"Suppression of GPR56 expression by pyrrole-imidazole polyamide represents a novel therapeutic drug for AML with high EVI1 expression"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"IRDB","@value":"oai:irdb.nii.ac.jp:00851:0006003764_CO39KTMK6pNvdbpiEADdOM9jcZX"}]}